Stichting Sanquin Bloedvoorziening

Gemini Therapeutics Sub, Inc.

Taco Willem Kuijpers

Maria Clara Brouwer

Richard Benjamin Pouw

Diana Wouters

Dirk Roos

Sridhar Govindarajan

Ilse Jongerius

Tom Purcell

Scott Lauder

Taede Rispens

Martin De Boer

Gillian Dekkers

Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.

Factor H potentiating antibodies and uses thereof

The invention relates to novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation.

The invention relates to isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation.

The invention provides improved methods for investigating nucleic acid sequences, wherein at least one additional probe is used which is specific for a (pseudo)gene variant of a target nucleic acid.

Means and methods for investigating nucleic acid sequences

The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the Fc&#x3b3;RII/Fc&#x3b3;RIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating Fc&#x3b3;R, and FCGR2B encoding an inhibitory Fc&#x3b3;R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.

Diagnostic methods involving determining gene copy numbers and SNPS in the Fc&#x3b3;RII/Fc&#x3b3;RIII gene cluster, and probes for use in such methods to detect susceptibility to and treatment efficacy in autoimmune diseases

The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the Fc&#x3b3;RII/Fc&#x3b3;RIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating Fc&#x3b3;R, and FCGR2B encoding an inhibitory Fc&#x3b3; R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.

Diagnostic methods involving determining gene copy numbers and SNPs in the FcyRII/FcyRIII gene cluster, and probes for use in such methods to detect susceptibility to and treatment efficacy in autoimmune diseases

Growing community of inventors

Amsterdam, Netherlands

Taco Willem Kuijpers